Making the investigational oncology pipeline more efficient and effective: Are we headed in the right direction?

Clinical Cancer Research

Volumn 16, Issue 24, 2010, Pages 5956-5962

  LoRusso, Patricia M ^a   Anderson, Aparna B ^b   Boerner, Scott A ^a   Averbuch, Steven D ^b  

^a WAYNE STATE UNIVERSITY   (United States)

^b BRISTOL MYERS SQUIBB   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

3 [1 (2,6 DICHLORO 3 FLUOROPHENYL)ETHOXY] 5 [1 (4 PIPERIDINYL) 1H PYRAZOL 4 YL] 2 PYRIDINYLAMINE; BEVACIZUMAB; GEFITINIB; GSK 1120212; PLX 4032; UNCLASSIFIED DRUG;

CANCER CHEMOTHERAPY; CANCER RESEARCH; CLINICAL TRIAL; COLORECTAL CANCER; DRUG APPROVAL; DRUG EFFICACY; DRUG SAFETY; DRUG SYNTHESIS; DRUG TOLERABILITY; HEALTH CARE POLICY; HUMAN; LUNG NON SMALL CELL CANCER; MELANOMA; PRIORITY JOURNAL; REVIEW; TREATMENT OUTCOME;

CLINICAL TRIALS, PHASE I AS TOPIC; CLINICAL TRIALS, PHASE II AS TOPIC; DRUGS, INVESTIGATIONAL; EFFICIENCY; HUMANS; MEDICAL ONCOLOGY; NEOPLASMS; PROFESSIONAL PRACTICE; THERAPIES, INVESTIGATIONAL; TREATMENT OUTCOME;

EID: 78650360228     PISSN: 10780432     EISSN: 15573265     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-10-1279     Document Type: Review

References (44)

1. LoRusso PM, Boerner SA, Seymour L. An overview of the optimal planning, design, and conduct of phase I studies of new therapeutics. Clin Cancer Res 2010;16:1710-8.
2. Pharmaceutical Research and Manufacturers of America (PhRMA). Medicines in development for cancer. 1987-2009; Available from: http://www.phrma.org.
3. ClinicalTrials.gov. Bethesda (MD): National Library of Medicine (US). 2000Available from:http://clinicaltrials.gov.
4. Simon R, Freidlin B, Rubinstein L, Arbuck SG, Collins J, Christian MC. Accelerated titration designs for phase I clinical trials in oncology. J Natl Cancer Inst 1997;89:1138-47.
5. Kinders R, Parchment RE, Ji J, et al. Phase 0 clinical trials in cancer drug development: from FDA guidance to clinical practice. Mol Interv 2007;7:325-34.
6. Kummar S, Kinders R, Gutierrez ME, et al. Phase 0 clinical trial of the poly (ADP-ribose) polymerase inhibitor ABT-888 in patients with advanced malignancies. J Clin Oncol 2009;27:2705-11.
7. Klamerus JF, Bruinooge SS, Ye X, et al. The impact of insurance on access to cancer clinical trials at a comprehensive cancer center. Clin Cancer Res 2010;16:5997-6003.
8. Hunsberger S, Rubinstein LV, Dancey J, Korn EL. Dose escalation trial designs based on a molecularly targeted endpoint. Stat Med 2005;24:2171-81. (Pubitemid 40960214)
9. Postel-Vinay S, Arkenau HT, Olmos D, et al. Clinical benefit in Phase-I trials of novel molecularly targeted agents: does dose matter? Br J Cancer 2009;100:1373-8.
10. Gupta S, Alqwasmi A, Hunsberger S, , et al. Dose of the molecularly targeted agents (MTA) in phase 1 trials correlates with clinical benefit. Presented at the 22nd EORTC-NCI-AACR symposium on Molecular Targets and Cancer Therapeutics; Berlin, Germany; 16-19 Nov 2010: abstract 363.
11. Fojo T, Parkinson DR. Biologically targeted cancer therapy and marginal benefits: are we making too much of too little or are we achieving too little by giving too much? Clin Cancer Res 2010;16:5972-80.
12. Cohen MH, Williams GA, Sridhara R, Chen G, Pazdur R. FDA drug approval summary: gefitinib (ZD1839) (Iressa) tablets. Oncologist 2003;8:303-6.
13. Thatcher N, Chang A, Parikh P, et al. Gefitinib plus best supportive care in previously treated patients with refractory advanced nonsmall-cell lung cancer: results from a randomised, placebo-controlled, multicentre study (Iressa Survival Evaluation in Lung Cancer). Lancet 2005;366:1527-37.
14. Stewart DJ, Whitney SN, Kurzrock R. Equipoise lost: ethics, costs, and the regulation of cancer clinical research. J ClinOncol 2010;28:2925-35.
15. Kim ES, Hirsh V, Mok T, et al. Gefitinib versus docetaxel in previously treated non-small-cell lung cancer (INTEREST): a randomised phase III trial. Lancet 2008;372:1809-18.
16. Mok TS, Wu YL, Thongprasert S, et al. Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma. N Engl J Med 2009;361:947-57.
17. Flaherty K, Puzanov I, Sosman J, et al. Phase I study of PLX4032: Proof of concept for V600E BRAF mutation as a therapeutic target in human cancer. J Clin Oncol 2009;27:9000.
18. Chapman P, Puzanov I, Sosman J, et al. Early efficacy signal demonstrated in advanced melanoma in a phase I trial of the oncogenic BRAF-selective inhibitor PLX4032. Eur J Cancer 2009;7:5.
19. Von Hoff DD, LoRusso PM, Rudin CM, et al. Inhibition of the hedgehog pathway in advanced basal-cell carcinoma. N Engl J Med 2009;361:1164-72.
20. Bang Y, Kwak EL, Shaw AT, et al. Clinical activity of the oral ALK inhibitor PF-02341066 in ALK-positive patients with non-small cell lung cancer (NSCLC). J Clin Oncol 2010;28:3.
21. Kwak EL, Camidge DR, Clark J, et al. Clinical activity observed in a phase I dose escalation trial of an oral c-met and ALK inhibitor, PF-02341066. J Clin Oncol 2009;27:3509.
22. Infante JR, Fecher LA, Nallapareddy S, et al. Safety and efficacy results from the first-in-human study of the oral MEK 1/2 inhibitor GSK1120212. J Clin Oncol 2010;28:2503.
23. Delord J, Houede N, Awada A, et al. First-in-human phase I safety, pharmacokinetic (PK), and pharmacodynamic (PD) analysis of the oral MEK-inhibitor AS703026 (two regimens [R]) in patients (pts) with advanced solid tumors. J Clin Oncol 2010;28:2504.
24. Borad MJ, Akerele CE, Ramanathan RK, et al. Phase I dose-escalation study of E6201, a MEK-1 inhibitor, in advanced solid tumors. J Clin Oncol 2010;28:2505.
25. Booth CM, Calvert AH, Giaccone G, Lobbezoo MW, Seymour LK, Eisenhauer EA. Endpoints and other considerations in phase I studies of targeted anticancer therapy: recommendations from the task force on Methodology for the Development of Innovative Cancer Therapies (MDICT). Eur J Cancer 2008;44:19-24. (Pubitemid 350256933)
26. Dalton WS, Sullivan DM, Yeatman TJ, Fenstermacher DA. The 2010 Health Care Reform Act: a potential opportunity to advance cancer research by taking cancer personally. Clin Cancer Res 2010;16:5987-96.
27. Centre for Medicines Research International. Pharmaceutical R&D Factbook. Epsom, Surrey, UK: Centre for Medicines Research International; 2006/2007.
28. Rubinstein L, Crowley J, Ivy P, Leblanc M, Sargent D. Randomized phase II designs. Clin Cancer Res 2009;15:1883-90.
29. George SL. Response rate as an endpoint in clinical trials. J Natl Cancer Inst 2007;99:98-9.
30. Therasse P, Arbuck SG, Eisenhauer EA, et al. New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst 2000;92:205-16.
31. Eisenhauer EA, Therasse P, Bogaerts J, et al. New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer 2009;45:228-47.
32. Booth CM, Calvert AH, Giaccone G, Lobbezoo MW, Eisenhauer EA, Seymour LK. Design and conduct of phase II studies of targeted anticancer therapy: recommendations from the task force on methodology for the development of innovative cancer therapies (MDICT). Eur J Cancer 2008;44:25-9.
33. Wang, Y. An example of disease model-non small cell lung cancer. (NSCLC). Presented at the FDA Advisory Committee for Pharmaceutical Science and Clinical Pharmacology (ACPS-PC), Mar 18-19, 2008. Rockville, MD.
34. Karrison TG, Maitland ML, Stadler WM, Ratain MJ. Design of phase II cancer trials using a continuous endpoint of change in tumor size: application to a study of sorafenib and erlotinib in non small-cell lung cancer. J Natl Cancer Inst 2007;99:1455-61.
35. Diggle PJ. An approach to the analysis of repeated measurements. Biometrics 1988;44:959-71.
36. Henderson R, Diggle P, Dobson A. Joint modelling of longitudinal measurements and event time data. Biostatistics 2000;1:465-80.
37. Wolchok JD, Hoos A, O'Day S, et al. Guidelines for the evaluation of immune therapy activity in solid tumors: immune-related response criteria. Clin Cancer Res 2009;15:7412-20.
38. Booth CM. Evaluating patient-centered outcomes in the randomized controlled trial and beyond: informing the future with lessons from the past. Clin Cancer Res 2010;16:5963-71.
39. Laurie JA, Moertel CG, Fleming TR, et al. Surgical adjuvant therapy of large-bowel carcinoma: an evaluation of levamisole and the combination of levamisole and fluorouracil. The North Central Cancer Treatment Group and the Mayo Clinic. J Clin Oncol 1989;7:1447-56.
40. Moertel CG, Fleming TR, Macdonald JS, et al. Levamisole and fluorouracil for adjuvant therapy of resected colon carcinoma. N Engl J Med 1990;322:352-8.
41. Kabbinavar F, Hurwitz HI, Fehrenbacher L, et al. Phase II, randomized trial comparing bevacizumab plus fluorouracil (FU)/leucovorin (LV) with FU/LV alone in patients with metastatic colorectal cancer. J Clin Oncol 2003;21:60-5.
42. Hurwitz H, Fehrenbacher L, Novotny W, et al. Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N Engl J Med 2004;350:2335-42.
43. Adjei AA, Christian M, Ivy P. Novel designs and end points for phase II clinical trials. Clin Cancer Res 2009;15:1866-72.
44. LoRusso PM, Stewart DJ, Boerner SA, Averbuch S, Schnipper LE, Wolf W. Translating clinical trials into meaningful outcomes. Clin Cancer Res 2010;16:5951-55.